Esketamine for depression faces real‐world barriers
Alcoholism & Drug Abuse Weekly October 7, 2019 DOI: 10.1002/adaw.32501 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Interventions | Esketamine Ketamine |
| Topics | Depression Esketamine |
| Key points | Esketamine (Spravato) has shown promise for treatment-resistant depression, and the FDA approved it in the spring for this indication, following the earlier off-label use of intravenous ketamine for depression. |
Abstract
Like its predecessor intravenous ketamine, an anesthetic that has been used off‐label to treat depression, esketamine has shown great promise in treating a disease that can destroy quality of life and lead to suicide. The Food and Drug Administration (FDA) approved esketamine (Spravato) last spring for treating depression that is resistant to traditional treatments.